Mylan and Pfizer have appointed Sanjeev Narula, current chief financial officer of Upjohn, a division of Pfizer, as incoming CFO of Viatris, the new company that will result from the planned combination of Mylan and Upjohn. Expected to close mid-2020, Viatris will have a portfolio of approximately 3,000 brands and molecules and a commercial presence in 165 countries. Mr. Narula spent 16 years with Pfizer serving in several financial leadership positions, and has worked under the leadership of...